Tonix Pharmaceuticals publishes presentation on TNX-4800 for Lyme disease prevention
TNXP•Tonix Pharmaceuticals published a medical research presentation on TNX-4800, an investigational Lyme disease prevention treatment. A planned adaptive Phase 2 field study is subject to FDA agreement on its final protocol, and manufacturing is on track for the first quarter of 2027.
1. Study and manufacturing plans
The planned adaptive Phase 2 field study remains subject to FDA agreement on the final protocol. Investigational product manufacturing is on track for the first quarter of 2027.
2. Phase 1 findings
Completed Phase 1 testing showed no significant clinical or laboratory safety signals; human preventive efficacy remains unestablished. The two-dose regimen targets protection within two days for at least six months.




